{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:10:05Z","timestamp":1789182605509,"version":"build-2803163510"},"reference-count":18,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2002,6,12]],"date-time":"2002-06-12T00:00:00Z","timestamp":1023840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Vinca alkaloids have proved active against a number of pediatric malignancies. The aim of this study was to assess the feasibility and effectiveness of using vinorelbine in previously treated pediatric patients with advanced sarcomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>From September 1998 to August 2001, 33 previously treated patients with progressive sarcoma were treated: 13 had rhabdomyosarcomas, 5 had other soft tissue sarcomas, 9 had Ewing sarcomas, and 6 had osteosarcomas. Vinorelbine was given intravenously on Days 1 and 8 of a 21\u2010day treatment cycle. Four patients with uncontrolled pain or central nervous system invasion received concurrent radiotherapy and were only evaluated for toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>One hundred seventy\u2010eight treatment cycles were administered (median of four per patient, range 1\u201320). Grade 3 to 4 neutropenia occurred in 63% of patients, Grade 3 anemia in 9%, and Grade 3 thrombocytopenia in 3%. Nonhematological toxicity was mild or moderate, i.e., always lower than Grade 3, with the exception of one child who experienced paralytic ileus. Twenty\u2010eight patients were assessable for response. Eight patients had a partial response, one patient had a minor response, and nine patients had stable disease. Objective responses were observed in 6 of 12 patients with rhadbomyosarcomas (five of six of the alveolar subtype), in one of five patients with osteosarcomas, and in one of seven patients with Ewing sarcomas. The median duration of response was 10 months (range, 3+ to 20).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Vinorelbine has a favorable toxicity profile with evidence of biological activity in already heavily treated pediatric patients with sarcomas. In particular, the objective response rate obtained for patients with alveolar rhabdomyosarcoma seems very promising. Due to the few cases considered here, further Phase II studies are needed to establish a potential role of vinorelbine in the treatment of these tumors. Cancer 2002;94:3263\u20138. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10600<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10600","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T08:29:56Z","timestamp":1033892996000},"page":"3263-3268","source":"Crossref","is-referenced-by-count":67,"title":["Vinorelbine in previously treated advanced childhood sarcomas"],"prefix":"10.1002","volume":"94","author":[{"given":"Michela","family":"Casanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Terenziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Massimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Luksch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Cefalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Polastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Marcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca Fossati","family":"Bellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,6,12]]},"reference":[{"issue":"2","key":"e_1_2_5_2_2","first-page":"9","article-title":"Biochemical effects of Navelbine on tubulin and associated proteins","volume":"16","author":"Fellous A","year":"1989","journal-title":"Semin Oncol."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(85)90186-7"},{"key":"e_1_2_5_4_2","first-page":"42","article-title":"A summary of vinorelbine (Navelbine) safety data from North American clinical trials","volume":"21","author":"Hohneker JA","year":"1994","journal-title":"Semin Oncol."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909709047587"},{"key":"e_1_2_5_6_2","first-page":"14","article-title":"The pharmacokinetics of vinorelbine (Navelbine) in pediatric cancer patients","author":"Madden T","year":"1995","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.annonc.a059101","article-title":"Current position of vinorelbine in cancer chemotherapy","volume":"6","author":"S\u00f8rensen JB","year":"1995","journal-title":"Ann Oncol."},{"key":"e_1_2_5_8_2","first-page":"168a","article-title":"Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH\/DANA Farber\/Partner's Cancer Care Study","volume":"17","author":"Fidias P","year":"1998","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.7.1550"},{"key":"e_1_2_5_10_2","first-page":"338","article-title":"Phase II study of vinorelbine in children and adolescents with refractory or recurrent cancer","volume":"29","author":"Epelman S","year":"1997","journal-title":"Med Pediatr Oncol."},{"key":"e_1_2_5_11_2","first-page":"147","article-title":"High response rate of vinorelbine in children and adolescents with refractory or recurrent rhabdomyosarcomas or other sarcomas","volume":"33","author":"Epelman S","year":"1999","journal-title":"Med Pediatr Oncol."},{"key":"e_1_2_5_12_2","volume-title":"NCI common toxicity criteria, version 1. Investigator's handbook: a manual of participants in clinical trials of investigational agents","author":"National Cancer Institute","year":"1993"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200105000-00008"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.12.3091"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930315)71:6<2119::AID-CNCR2820710629>3.0.CO;2-Y"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.2.308"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199807000-00006"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.213"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200108000-00002"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10600","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:20:58Z","timestamp":1760296858000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10600"}},"subtitle":["Evidence of activity in rhadbomyosarcoma"],"short-title":[],"issued":{"date-parts":[[2002,6,12]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,6,15]]}},"alternative-id":["10.1002\/cncr.10600"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10600","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,12]]}}}